Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006345 · ClinicalTrials.gov registry record · Phase 2
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
A Phase 2 study, sponsored by Ligand Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006345: Completed Phase 2 study, sponsored by Ligand Pharmaceuticals.
NCT00006345 is a Phase 2 study that has completed, run by Ligand Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006345, a Phase 2 study, has completed, sponsored by Ligand Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox. PURPOSE: Phase II trial to study the effectiveness of dexamethasone in preventing side effects following treatment with denileukin diftitox in treating patients who have persistent or recurrent T-cell lymphoma.
Interventions
- DRUG dexamethasone
- BIOLOGICAL denileukin diftitox
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-11 |
| Est. Completion | 2004-03 |
| Phase | Phase 2 |
What the finished NCT00006345 record still lists
NCT00006345 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which dexamethasone is the first listed.
NCT00006345 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006345 about?
NCT00006345 is a clinical study titled "Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma". RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox. PURPOSE: Phase II trial to study the effectiveness of dexamethasone in preventing side effects following treatment w...
What is the current status of trial NCT00006345?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-11. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00006345?
The interventions under investigation include: dexamethasone (DRUG), denileukin diftitox (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006345?
This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia